Intellia Therapeutics, Inc. - Common Stock (NTLA)
6.8700
-0.5800 (-7.79%)
NASDAQ · Last Trade: May 31st, 8:57 PM EDT
Detailed Quote
Previous Close | 7.450 |
---|---|
Open | 7.430 |
Bid | 6.970 |
Ask | 7.000 |
Day's Range | 6.830 - 7.430 |
52 Week Range | 5.900 - 28.18 |
Volume | 8,853,703 |
Market Cap | 605.53M |
PE Ratio (TTM) | -1.316 |
EPS (TTM) | -5.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,599,357 |
Chart
About Intellia Therapeutics, Inc. - Common Stock (NTLA)
Intellia Therapeutics is a biotechnology company focused on developing innovative gene-editing therapies to treat serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 technology platform to create precise and effective treatments that have the potential to address the root causes of diseases. By advancing its research and clinical programs, Intellia aims to pioneer new therapeutic approaches that could significantly improve patient outcomes and transform the landscape of genetic medicine. Read More
News & Press Releases

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.
Via Benzinga · May 30, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · May 29, 2025

The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.
Via Stocktwits · May 29, 2025

Via Benzinga · May 29, 2025

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.
Via Benzinga · May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · May 29, 2025

Via Benzinga · May 29, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · May 29, 2025

Via Benzinga · May 29, 2025

Via Benzinga · May 29, 2025

Via Benzinga · May 28, 2025
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Via MarketBeat · May 23, 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
Via Benzinga · May 12, 2025
Via Benzinga · May 12, 2025
The popular growth investor keeps adding to some of her favorite stocks.
Via The Motley Fool · April 30, 2025
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.
Via Benzinga · April 26, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via Investor's Business Daily · April 21, 2025
Via Benzinga · April 21, 2025
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · April 14, 2025
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) and reminds investors of the April 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · April 14, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 13, 2025